Merus (NASDAQ:MRUS) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Wednesday.
Other equities research analysts also recently issued reports about the stock. ValuEngine downgraded shares of Merus from a “buy” rating to a “hold” rating in a research note on Monday, September 24th. Zacks Investment Research downgraded shares of Merus from a “buy” rating to a “hold” rating in a research note on Friday, November 9th.
Shares of NASDAQ:MRUS opened at $14.39 on Wednesday. Merus has a 52-week low of $11.00 and a 52-week high of $26.74.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Read More: What are no-load funds?
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.